Natera Ovarian Cancer Detection Assay

Natera, Inc.12 enrolled

Overview

The purpose of this study is to enroll participants who present with an adnexal mass on imaging to develop a non-invasive ovarian cancer assay to distinguish between malignant and benign masses. The study will collect blood, tissue, and health information from these individuals.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Adnexal Mass

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Presenting to clinic with adnexal mass suspicious of ovarian, fallopian tube, or peritoneal cancer on imaging * Must be planning surgical resection or biopsy * Must be treatment naïve * Must be 18 years or older * Able to understand and sign a written informed consent document * Able to provide 40mL of blood (at least 20mL) for each blood draw Exclusion Criteria: * Prior removal of either ovary for any reason * Currently pregnant * Blood transfusion within 3 months of study enrollment * History of bone marrow or organ transplant * Prior history and treatment for any malignancy, with exception of previously treated non-melanoma skin cancer. * A medical condition that would place subject at risk as a result of the blood donation, including but not limited to bleeding disorders, chronic infectious disease, emphysema or serious anemia

Locations (1)

Magee-Women's Hospital of UPMC

Pittsburgh, Pennsylvania, United States

Outcomes

Primary Outcomes

Compare ctDNA from benign ovarian masses and confirmed ovarian cancers

Examine ctDNA between benign ovarian masses and confirmed ovarian cancer cases (based on tumor pathology report). The purpose of this outcome is to determine whether cfDNA could be used to develop a non-invasive ovarian cancer assay to distinguish between malignant and benign masses.

Time frame: Up to 60 months or 5 years

Secondary Outcomes

Determine the relationship between quantity of ctDNA and standard prognostic criteria

Examine quantity of ctDNA and standard prognostic criteria such as tumor grade, histology and stage of cancer

Time frame: Up to 60 months or 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.